oa The genetic association of CYP2C19 allele with clopidogrel treatment in myocardial infarction

Major adverse cardiac events, including thrombosis and cardiac stroke, represent life-threatening conditions that need to be analyzed from every perspective including: life-style and genetic background. There is growing evidence that such ischemic events are more prone to arise in populations with a certain genetic background. With appropriate treatment and significant improvements in technology, genetics analysis of many diseases has become readily available and are easier to perform. In this paper we studies the genetic association of CYP2C19 allelic variants *2,*5 and *17 polymorphisms on the response to clopidogrel antipla telet treatment in post-myocardial infarction patients.

5 ml of blood was drawn from 42 cardiac patients on antiplatelet therapy. For the detection of the CYP2C19*5, CYP2C19*17, CYP2C19*2, extracted DNA was carried out by the 5’ nuclease assay using TaqMan MGB probe by means of an ABI 7900 [Applied Biosystems).

Results have shown that there is significant association between CYP2C19*17 mutation and clinical outcome in TT patients carrying the mutant allele (p=0.048). As for CYP2C19*5 (p=0.917) and CYP2C19*2(p=0.09) mutations results have shown no significant association between CYP2C19*5 and *2 response to plavix, although CT/TT and GA/AA mutations have shown more recurrent ischemic events and death than wild type genotypes.

Mutations in CYP2C19*17 has an effect on clopidogrel response, while CYP2C19*2 and *5 are not significantly associated with such low response. Further studies are needed with a larger sample size.